Conquering homocystinuria with engineered probiotics

Skye R.S. Fishbein; Esse M. Evbuomwan; Gautam Dantas

doi:10.1016/j.chom.2024.02.008

Conquering homocystinuria with engineered probiotics

Skye R.S. Fishbein
, Esse M. Evbuomwan
, Gautam Dantas

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Abstract

Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.

Original language	English
Pages (from-to)	298-300
Number of pages	3
Journal	Cell Host and Microbe
Volume	32
Issue number	3
DOIs	https://doi.org/10.1016/j.chom.2024.02.008
State	Published - Mar 13 2024

Access to Document

10.1016/j.chom.2024.02.008

Cite this

@article{e86f7c66446c4bdaa150d293a49c345e,

title = "Conquering homocystinuria with engineered probiotics",

abstract = "Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.",

author = "Fishbein, \{Skye R.S.\} and Evbuomwan, \{Esse M.\} and Gautam Dantas",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2024",

month = mar,

day = "13",

doi = "10.1016/j.chom.2024.02.008",

language = "English",

volume = "32",

pages = "298--300",

journal = "Cell Host and Microbe",

issn = "1931-3128",

number = "3",

}

TY - JOUR

T1 - Conquering homocystinuria with engineered probiotics

AU - Fishbein, Skye R.S.

AU - Evbuomwan, Esse M.

AU - Dantas, Gautam

PY - 2024/3/13

Y1 - 2024/3/13

N2 - Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.

AB - Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.

UR - https://www.scopus.com/pages/publications/85187007283

U2 - 10.1016/j.chom.2024.02.008

DO - 10.1016/j.chom.2024.02.008

M3 - Comment/debate

C2 - 38484708

AN - SCOPUS:85187007283

SN - 1931-3128

VL - 32

SP - 298

EP - 300

JO - Cell Host and Microbe

JF - Cell Host and Microbe

IS - 3

ER -

Conquering homocystinuria with engineered probiotics

Abstract

Access to Document

Other files and links

Fingerprint

Cite this